The Safety of Thoracentesis, Tunneled Pleural Catheter (Pleurx), and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants (NOAC).
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 590
- 试验地点
- 1
- 主要终点
- Risk of bleeding
研究概览
简要总结
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
详细描述
The research component of this study simply observes and documents the outcomes of these procedures. Patients will undergo an analysis of their pre-procedural hematocrit and this will be compared to their post-procedural (next day) hematocrit.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 y/o
- •Unilateral or bilateral pleural effusion
- •Ability to provide consent or consent given for the procedure and research study
排除标准
- •Adults who refuse to provide consent.
研究组 & 干预措施
patients taking NOAC's
Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
干预措施: Novel Oral Anti-Coagulants (Drug)
结局指标
主要结局
Risk of bleeding
时间窗: 2 years
Reduced risk of bleeding in individuals receiving Novel Oral Anti-Coagulants as well as those that are in the control group will be assessed by having the patients undergo an analysis of their pre-procedural hematocrit which will be compared to their post procedural (next day) hematocrit
次要结局
未报告次要终点